Futura Medical PLC
07 October 2026
7 October 2026
Futura Medical plc
(“Futura” or the “Company”)
Positive results from Additional Eroxon® “Intense” Home User Test
Futura Medical plc (AIM:FUM) the consumer healthcare company behind Eroxon® and that specialises in the development and commercialisation of innovative and clinically proven sexual health products, is pleased to report the results of an additional recent Home User Test (“HUT”) conducted on the new Eroxon® “Intense” formula intended for commercialisation in H1 2027.
The HUT tested the “Intense” formula with its proven sensorial enhancement over the current Eroxon® product with an optimised product presentation designed to support more consistent dispensing and application in real world use.
Results were highly positive demonstrating a significant improvement in product performance over the original Intense presentation and Eroxon® formulation.
Home User Test results summary
The study evaluated Intense with the optimised Intense presentation in 115 men aged 18-59, the majority of whom had mild to moderate erectile dysfunction. The study design was broadly identical to the previous Home User Test, detailed in the announcement on 23 March 2026, allowing direct comparison between the two studies.
Results demonstrated that the optimised presentation improved performance across all key measures compared with both the original Intense presentation and the current Eroxon® formulation.
Participants reported being satisfied with the hardness of their erections in 82% of sexual encounters, compared with 71% for the original Intense and 70% for Eroxon® in the previous study. Erections lasted long enough for intercourse in 87% of encounters, compared with 85% and 84% respectively.
On the clinically validated IIEF-EF scale*, participants achieved a 7.86-point improvement from baseline, compared with 4.82 points in the previous study of original Intense. This exceeded the threshold generally regarded as clinically meaningful** and was particularly pronounced among men with moderate ED, where 87% achieved a clinically meaningful improvement versus 73% previously.
Ratings, user satisfaction and purchase intent all improved compared with the previous study on the original Eroxon Intense presentation, further supporting the enhanced performance of the optimised Intense presentation.
In summary, the optimised Intense presentation delivered meaningful improvements across all key performance measures, reinforcing the potential of Intense to provide a differentiated consumer experience. Work is now nearing completion to finalise the product's market positioning ahead of the planned H1 2027 launch. The results further support the Company's previously stated belief that clear communication around product use will deliver increased customer satisfaction.
*Rosen, Riley, Wagner, Osterioh, Kirkpatrick and Mishra. Urology. Volume 49, Issue 6, June 1997, pages 822-830
**Rosen, Allen, Ni and Araujo. Eur Urol, 2011 Nov; 60(5) 1010-6
Ken James, Executive Director and Head of R&D commented:"We are very encouraged by the results of this additional Home User Test. The optimised presentation of the new Intense product delivered improvements across all key measures compared with previous study results on both the original Intense the current Eroxon® formulations/presentations, demonstrating the potential to further enhance the user experience.
Importantly, the study continues to reinforce our belief that Intense’s enhanced sensorial experience represents a meaningful point of differentiation. As we have highlighted previously, effective positioning and communication around the use of the product will be critical in improving customer satisfaction.
With launch development progressing well, we remain on track to complete the brand positioning work and prepare for the planned commercial launch in the first half of 2027."
Contacts:
|
Futura Medical plc
|
Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Joint Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0) 20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd -Joint Broker and Retail Offer Coordinator |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0) 20 3405 0205 futura@almastrategic.com |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for Futura's development female sexual health portfolio, starting with the creation of a range of topical gels under Futura's unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication, ability to orgasm and overall sexual satisfaction.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.